{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:45:53Z","timestamp":1773287153263,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.diabres.2018.08.015","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:18:48Z","timestamp":1536207528000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of \u03b2- and \u03b1-cells to GLP-1 stimulation and the glycaemic control at 6\u202fmonths after switching therapy"],"prefix":"10.1016","volume":"144","author":[{"given":"Ichiro","family":"Horie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Akeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Niri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyoko","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Natsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2018.08.015_b0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00125-009-1321-z","article-title":"The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality","volume":"52","author":"Kahn","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2018.08.015_b0010","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.08.015_b0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabres.2018.08.015_b0020","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2018.08.015_b0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.08.015_b0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2337\/diaspect.29.3.152","article-title":"Basal insulin use with GLP-1 receptor agonists","volume":"29","author":"Anderson","year":"2016","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.diabres.2018.08.015_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2018.08.015_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.2040-1124.2012.00242.x","article-title":"Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin","volume":"4","author":"Nambu","year":"2013","journal-title":"J Diabetes Investig."},{"key":"10.1016\/j.diabres.2018.08.015_b0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdiacomp.2012.07.001","article-title":"Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes","volume":"27","author":"Iwao","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2018.08.015_b0050","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.diabres.2012.09.036","article-title":"C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment","volume":"98","author":"Takabe","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2018.08.015_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.diabres.2017.12.006","article-title":"Insulin tolerance test predicts non response vs. sustained efficacy of liraglutide on glycemic control in type 2 diabetes patients: a prospective real-world setting study","volume":"137","author":"Germain","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.diabres.2018.08.015_b0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jdi.12773","article-title":"Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: the association between remaining beta-cell function and the achievement of the glycated hemoglobin target 1 year after initiation","volume":"9","author":"Usui","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2018.08.015_b0065","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.12829","article-title":"Sex differences in insulin and glucagon responses for glucose homeostasis in young healthy Japanese adults","author":"Horie","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2018.08.015_b0070","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-014-3283-z","article-title":"Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?","volume":"57","author":"Wewer Albrechtsen","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2018.08.015_b0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jdi.12400","article-title":"Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay","volume":"7","author":"Matsuo","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2018.08.015_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3164\/jcbn.13-14","article-title":"Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes","volume":"53","author":"Matsumoto","year":"2013","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/j.diabres.2018.08.015_b0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1758-5996-6-110","article-title":"Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes","volume":"6","author":"Imai","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabres.2018.08.015_b0090","first-page":"289","article-title":"Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide","volume":"39","author":"Haraguchi","year":"2014","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.diabres.2018.08.015_b0095","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"U.K. prospective diabetes study 16","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2018.08.015_b0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00586459","article-title":"Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus","volume":"33","author":"Snorgaard","year":"1990","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2018.08.015_b0105","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1152\/ajpendo.2000.279.3.E520","article-title":"Overnight inhibition of insulin secretion restores pulsatility and proinsulin\/insulin ratio in type 2 diabetes","volume":"279","author":"Laedtke","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabres.2018.08.015_b0110","first-page":"1806","article-title":"Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome","volume":"79","author":"Haffner","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2018.08.015_b0115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.27.6.1433","article-title":"Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of type 2 diabetes: a population-based, 7-year follow-up study in 70-year-old men","volume":"27","author":"Zethelius","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.08.015_b0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1464-5491.2010.03191.x","article-title":"Proinsulin\/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults","volume":"28","author":"Scholin","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2018.08.015_b0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2018.08.015_b0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2018.08.015_b0135","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.08.015_b0140","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2018.08.015_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2018.08.015_b0150","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2018.08.015_b0155","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2337\/db09-1899","article-title":"Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?","volume":"59","author":"Meier","year":"2010","journal-title":"Diabetes"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271830874X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271830874X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T01:01:33Z","timestamp":1540083693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882271830874X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"alternative-id":["S016882271830874X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2018.08.015","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of \u03b2- and \u03b1-cells to GLP-1 stimulation and the glycaemic control at 6\u202fmonths after switching therapy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2018.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}